Humacyte, Inc. announced the first preclinical results of the use of Humacyte's Human Acellular Vessel™ (HAV) in coronary artery bypass grafting (CABG) will be presented at the Advanced Therapies Week conference in Miami, Fla. at 9:20 a.m. EST on January 28, 2022. The presentation, titled “Bioengineering and the Future of Cardiac Surgery,” will be made by Alan P. Kypson, M.D., FACS.

Dr. Kypson is a cardiothoracic surgeon at the University of North Carolina Rex Hospital in Raleigh, N.C., and a thought leader in the field of cardiac surgery who has led the large animal preclinical development of Humacyte's vessels in CABG for more than a decade. The presentation by Dr. Kypson will include the results of the use of the HAV in a primate CABG model, including six-month outcomes. Humacyte's HAVs are engineered off-the-shelf replacement vessels that are currently being evaluated in advanced-stage clinical trials in vascular trauma, arteriovenous access for hemodialysis, and peripheral arterial disease.

CABG surgery, which treats blockage of the coronary arteries to restore the blood supply to the heart muscle, is performed more than 350,000 times annually in the United States, with over 765,000 annual CABG procedures globally. Humacyte's program is designed to develop a small-diameter HAV as a potential alternative to existing vascular substitutes during CABG surgery, particularly in obese or diabetic patients, where the risks of saphenous vein harvesting are substantial.